Henry Mark Kuerer

Henry Mark Kuerer

Auto-generated profile, based on publicly available information

Henry Mark Kuerer

Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ACAbigail S. Caudle
Abigail S. Caudle
WYWei T. Yang
Wei T. Yang
SKSavitri Krishnamurthy
Savitri Krishnamurthy
EMElizabeth A. Mittendorf
Elizabeth A. Mittendorf
DBDalliah M. Black
Dalliah M. Black
HKHenry M. Kuerer
Henry M. Kuerer
Purpose: Placing clips in nodes with biopsy-confirmed metastasis before initiating neoadjuvant therapy allows for evaluation of response in breast cancer. Our goal was to determine if pathologic changes in clipped nodes reflect the status of the nodal basin and if targeted axillary dissection (TAD), which includes sentinel lymph node dissection (SLND) and selective localization and removal of clipped nodes, improves the false-negative rate (FNR) compared with SLND alone.Methods: A prospective study of patients with biopsy-confirmed nodal metastases with a clip placed in the sampled node was performed. After neoadjuvant therapy, patients underwent axillary surgery and the pathology of the clipped node was compared with other nodes. Patients undergoing TAD had SLND and selective removal of the clipped node using iodine-125 seed localization. The FNR was determined in patients undergoing complete axillary lymphadenectomy (ALND).Results: Of 208 patients enrolled in this study, 191 underwent ALND, with residual disease identified in 120 (63%). The clipped node revealed metastases in 115 patients, resulting in an FNR of 4.2% (95% CI, 1.4 to 9.5) for the clipped node. In patients undergoing SLND and ALND (n = 118), the FNR was 10.1% (95% CI, 4.2 to 19.8), which included seven false-negative events in 69 patients with residual disease. Adding evaluation of the clipped node reduced the FNR to 1.4% (95% CI, 0.03 to 7.3; P = .03). The clipped node was not retrieved as an SLN in 23% (31 of 134) of patients, including six with negative SLNs but metastasis in the clipped node. TAD followed by ALND was performed in 85 patients, with an FNR of 2.0% (1 of 50; 95% CI, 0.05 to 10.7).Conclusion: Marking nodes with biopsy-confirmed metastatic disease allows for selective removal and improves pathologic evaluation for residual nodal disease after chemotherapy.

9 September 2007 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
HKHenry M. Kuerer
Henry M. Kuerer
TETimothy J. Eberlein
Timothy J. Eberlein
RPRaphael E. E Pollock
Raphael E. E Pollock
MHMashele Huschka
Mashele Huschka
WBWalter F. Baile
Walter F. Baile
TSTait D. Shanafelt
Tait D. Shanafelt

11 June 2010 in Cancer
Verified
Journal Article
Open access
PDF file
LDLaura S. Dominici
Laura S. Dominici
VGViviana M. Negron Gonzalez
Viviana M. Negron Gonzalez
ABAman U. Buzdar
Aman U. Buzdar
ALAnthony Lucci
Anthony Lucci
EMElizabeth A. Mittendorf
Elizabeth A. Mittendorf
HKHenry M. Kuerer
Henry M. Kuerer
BACKGROUND: The axillary pathologic complete response rate (pCR) and the effect of axillary pCR on disease‐free survival (DFS) was determined in patients with HER2‐positive breast cancer and biopsy‐proven axillary lymph node metastases who were receiving concurrent trastuzumab and neoadjuvant chemotherapy. The use of neoadjuvant chemotherapy is reported to result in pCR in the breast and axilla in up to 25% of patients. Patients achieving a pCR have improved DFS and overall survival. To the authors' knowledge, the rate of eradication of biopsy‐proven axillary lymph node metastases with trastuzumab‐containing neoadjuvant chemotherapy regimens has not been previously reported.METHODS: Records were reviewed of 109 consecutive patients with HER2‐positive breast cancer and axillary metastases confirmed by ultrasound‐guided fine‐needle aspiration biopsy who received trastuzumab‐containing neoadjuvant chemotherapy followed by breast surgery with complete axillary lymph node dissection. Survival was evaluated by the Kaplan‐Meier method. Clinicopathologic factors and DFS were compared between patients with and without axillary pCR.RESULTS: Eighty‐one patients (74%) achieved a pCR in the axilla. Axillary pCR was not associated with age, estrogen receptor status, grade, tumor size, initial N classification, or median number of lymph nodes removed. More patients with an axillary pCR also achieved a pCR in the breast (78% vs 25%; P < .001). At a median follow‐up of 29.1 months, DFS was significantly greater in the axillary pCR group (P = .02).CONCLUSIONS: Trastuzumab‐containing neoadjuvant chemotherapy appears to be effective in eradicating axillary lymph node metastases in the majority of patients treated. Patients who achieve an axillary pCR are reported to have improved DFS. The success of pCR with concurrent trastuzumab and chemotherapy in eradicating lymph node metastases has implications for surgical management of the axilla in these patients. Cancer 2010. © 2010 American Cancer Society.

1 July 2017 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
ATAudree B. Tadros
Audree B. Tadros
WYWei T. Yang
Wei T. Yang
SKSavitri Krishnamurthy
Savitri Krishnamurthy
GRGaiane M. Rauch
Gaiane M. Rauch
BSBenjamin D. Smith
Benjamin D. Smith
HKHenry M. Kuerer
Henry M. Kuerer
The dramatic therapeutic effects of neoadjuvant chemotherapy (NCT) in the breast and documented nodal metastases has been demonstrated for several decades.1-3 During this time, our understanding of the biology of breast cancer, response to NCT, and integration of these findings into clinical practice has changed the surgical management of breast cancer. A pathologic complete response (pCR) in the breast (hereinafter referred to as breast pCR) to NCT, defined as no residual invasive or in situ disease, is known to confer disease-free and overall survival benefits.1,4,5 The variability of breast pCR rates among different subtypes of breast cancer has been extensively studied. Patients with HER2 (now ERBB2)-positive (HER2+)/triple-negative (TN) subtypes have a higher incidence of breast pCR than patients with luminal type A or B.6,7 Tumor size is also an independent predictor of pCR, with T1 and T2 tumors having higher rates of pCR than T3 or T4 tumors. The implementation of dual systemic agent therapy for breast cancer targeting human epidermal growth factor receptor 2 is now routinely incorporated for patients with HER2+ tumors.8 This process has led to increased rates of breast pCR among patients with the HER2+ subtype.9

25 October 2022 in The Lancet Oncology
Verified
Journal Article
Closed access
HKHenry M Kuerer
Henry M Kuerer
BSBenjamin D Smith
Benjamin D Smith
SKSavitri Krishnamurthy
Savitri Krishnamurthy
WYWei T Yang
Wei T Yang
VVVicente Valero
Vicente Valero
SSSimona F Shaitelman
Simona F Shaitelman

1 January 2011 in Journal of Cancer
Verified
Journal Article
Open access
SLSara A. Lari
Sara A. Lari
HKHenry M. Kuerer
Henry M. Kuerer
Understanding of the biology and clinical behavior of ductal carcinoma in situ (DCIS) is currently inadequate. The aim of this comprehensive review was to identify important molecular biological markers associated with DCIS and candidate markers associated with increased risk of ipsilateral recurrence after diagnosis of DCIS. A comprehensive systematic review was performed to identify studies published in the past 10 years that investigated biological markers in DCIS. To be included in this review, studies that investigated the rate of biological expression of markers had to report on at least 30 patients; studies that analyzed the recurrence risk associated with biomarker expression had to report on at least 50 patients. There were 6,252 patients altogether in our review. Biological markers evaluated included steroid receptors, proliferation markers, cell cycle regulation and apoptotic markers, angiogenesis-related proteins, epidermal growth factor receptor family receptors, extracellular matrix-related proteins, and COX-2. Although the studies in this review provide valuable preliminary information regarding the expression and prognostic significance of biomarkers in DCIS, common limitations of published studies (case-series, cohort, and case-control studies) were that they were limited to small patient cohorts in which the extent of surgery and use of radiotherapy or endocrine therapy varied from patient to patient, and variable methods of determining biomarker expression. These constraints made it difficult to interpret the absolute effect of expression of various biomarkers on risk of local recurrence. No prospective validation studies were identified. As the study of biomarkers are in their relative infancy in DCIS compared with invasive breast cancer, key significant prognostic and predictive markers associated with invasive breast cancer have not been adequately studied in DCIS. There is a critical need for prospective analyses of novel and other known breast cancer molecular markers in large cohorts of patient with DCIS to differentiate indolent from aggressive DCIS and better tailor the need and extent of current therapies.